Super bowl advertising on weight loss drugs calls for “broken” health care in America; Senators express their concern |

Even before Hims & Hers, a TV company should broadcast their advertising on Sunday, during the Super Bowl Lix, he drew the attention of Americans and administrators.
The announcement speaks of “the deadliest epidemic in America”, obesity, and takes a search for the “broken” health system in America.
Before broadcasting the announcement on Sunday, the company launched it online, generating a lot of buzz. The announcement questions the weight loss industry of $ 160 billion and shows a person who selects the company’s weight loss offers via a smartphone.
“The system was not built to help us. It was designed to keep us sick and stuck, ”explains the announcement. Although the announcement does not identify the drug, it offers versions composed of semaglutide, a weight loss drug originally developed by Novo Nordisk and commonly marketed under the Wegovy and Ozempic brand names.
The critical announcement Weight loss drugs Currently available on the market as something “prices for profits, not patients”. According to Hims & Hers, they rather offer “accessible and affordable” alternatives which are “reliable by medical experts”.
The partnership for SAFE drugs, which is a group made up of more than 40 community and pharmacy groups, urged Food and Drug Administration (FDA) to protect Americans from “misleading marketing” in health products.
Two American senators – Sens. Dick Durbin, d-ill., And Roger Marshall, r-kan., Wrote a letter at the FDA, expressing concern. “An upcoming advertising of the Super Bowl, publicly published online, seems to present the ability of a company to prescribe and distribute GLP-1 drugs to patients, including with text and affirmations on weight loss drugs , and the imagery of an injection pen with distinct characteristics reflecting an existing brand medication. However, nowhere in this promotion, there is information of disclosure, risk or safety with side effects, as would generally be necessary in pharmaceutical advertising. In comparison, labels and advertisements approved by the FDA for the brand’s GLP-1 drugs include significant risk disclosure for patients on side effects and contraindications, including warnings on potential gallbladder, Pancreas, vomiting, diarrhea and other implications. In addition, for only three seconds during one -minute advertising, the screen flashes in a barely readable police, that these products are not approved by the FDA. »»

Meanwhile, in a press release, Hims & Hers said that the pharmaceutical industry is trying to cancel an advertisement that “directly explains how they are part of a system that does not favor the health of Americans. The system is broken, and this is an other example of how they don’t want Americans to know that they have options. »»
(Picked picked up: ad screen))